Search
for
Sort by
Research 331–360 of 923
- Eyelash Trichomegaly: A Rare Presenting Feature of Systemic Lupus Erythematosus.
- Eyelash trichomegaly: Report of a case following diffuse hair loss associated with transient malnutrition
- Postburns hair restoration of eyebrow, eyelash, moustache, beard and scalp areas
- Hypothyroidism, eyelash loss
- Retrospective Review of Eyelash Number in Patients Who Have Undergone Full-Thickness Eyelid Resection
- Aesthetic Eyelash Elongation for Asians Using a Dense-Packing Single-Hair Grafting Technique
- Eyelash trichomegaly complicating pembrolizumab for colorectal cancer
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Latanoprost for Eyelash Growth in Aesthetic Medicine
- Bimatoprost solution 0·03% topical application to the eyelid margin for the treatment of eyelash hypotrichosis
- Treatment of Vitiligo Associated Eyebrow and Eyelash Leukotrichia - A Systematic Review of Existing Information
- Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Jarilla–Coffea extract: a natural cosmetic product that improves eyelash and eyebrow growth in women
- Multi-Herbal Extracellular Vesicle and Growth Factor Serum for Eyelash Care: A Pilot Randomized, Double Blind, Placebo-Controlled Clinical Study
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- PCR108 QUALITATIVE AND PSYCHOMETRIC EVALUATION OF THE CLINRO MEASURE FOR EYEBROW HAIR LOSS AND CLINRO MEASURE FOR EYELASH HAIR LOSS IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Eyebrow and Eyelash Transplantation Using Chalazion Forceps (Dr. Min’s Method) and Importance of Post-Transplant Recovery in Hair Restoration
- An Approach to Performing Successful Eyelash Restoration
- 63532 Impact of Eyebrow and Eyelash Hair Loss on Health-Related Quality of Life Among Patients with Alopecia Areata: Results From a Real-World Survey in 5 European Countries
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib
- Progressive Eyelash Loss and Scale of the Right Eyelid
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials